343 related articles for article (PubMed ID: 35140181)
1. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
Kidani Y; Nogami W; Yasumizu Y; Kawashima A; Tanaka A; Sonoda Y; Tona Y; Nashiki K; Matsumoto R; Hagiwara M; Osaki M; Dohi K; Kanazawa T; Ueyama A; Yoshikawa M; Yoshida T; Matsumoto M; Hojo K; Shinonome S; Yoshida H; Hirata M; Haruna M; Nakamura Y; Motooka D; Okuzaki D; Sugiyama Y; Kinoshita M; Okuno T; Kato T; Hatano K; Uemura M; Imamura R; Yokoi K; Tanemura A; Shintani Y; Kimura T; Nonomura N; Wada H; Mori M; Doki Y; Ohkura N; Sakaguchi S
Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35140181
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
3. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
Weaver JD; Stack EC; Buggé JA; Hu C; McGrath L; Mueller A; Wong M; Klebanov B; Rahman T; Kaufman R; Fregeau C; Spaulding V; Priess M; Legendre K; Jaffe S; Upadhyay D; Singh A; Xu CA; Krukenberg K; Zhang Y; Ezzyat Y; Saddier Axe D; Kuhne MR; Meehl MA; Shaffer DR; Weist BM; Wiederschain D; Depis F; Gostissa M
Oncoimmunology; 2022; 11(1):2141007. PubMed ID: 36352891
[TBL] [Abstract][Full Text] [Related]
5. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.
Roider HG; Hoff S; Tseng SY; Berndt S; Trautwein M; Filarsky K; Gritzan U; Camps J; Nadler WM; Grudzinska-Goebel J; Ellinger P; Pesch T; Soon CF; Geyer M; Gluske K; Stelte-Ludwig B; Gorjánácz M
Clin Exp Med; 2024 Jun; 24(1):122. PubMed ID: 38856863
[TBL] [Abstract][Full Text] [Related]
6. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
[TBL] [Abstract][Full Text] [Related]
7. CD4
Liu S; Tao Z; Lou J; Li R; Fu X; Xu J; Wang T; Zhang L; Shang W; Mao Y; Wang F
J Transl Med; 2023 Nov; 21(1):803. PubMed ID: 37950246
[TBL] [Abstract][Full Text] [Related]
8. CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.
Whiteside SK; Grant FM; Gyori DS; Conti AG; Imianowski CJ; Kuo P; Nasrallah R; Sadiyah F; Lira SA; Tacke F; Eil RL; Burton OT; Dooley J; Liston A; Okkenhaug K; Yang J; Roychoudhuri R
Immunology; 2021 Aug; 163(4):512-520. PubMed ID: 33838058
[TBL] [Abstract][Full Text] [Related]
9. S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells.
Nagira Y; Nagira M; Nagai R; Nogami W; Hirata M; Ueyama A; Yoshida T; Yoshikawa M; Shinonome S; Yoshida H; Haruna M; Miwa H; Chatani N; Ohkura N; Wada H; Tanaka H
Mol Cancer Ther; 2023 Sep; 22(9):1063-1072. PubMed ID: 37420296
[TBL] [Abstract][Full Text] [Related]
10. In situ analysis of CCR8
Hayashi Y; Ueyama A; Funaki S; Jinushi K; Higuchi N; Morihara H; Hirata M; Nagira Y; Saito T; Kawashima A; Iwahori K; Shintani Y; Wada H
BMC Cancer; 2024 May; 24(1):627. PubMed ID: 38783281
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile.
Ueyama A; Nogami W; Nashiki K; Haruna M; Miwa H; Hagiwara M; Nagira M; Wada H; Nagira Y
J Immunol; 2023 Aug; 211(4):673-682. PubMed ID: 37350632
[TBL] [Abstract][Full Text] [Related]
12. The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer.
Haruna M; Ueyama A; Yamamoto Y; Hirata M; Goto K; Yoshida H; Higuchi N; Yoshida T; Kidani Y; Nakamura Y; Nagira M; Kawashima A; Iwahori K; Shintani Y; Ohkura N; Wada H
Sci Rep; 2022 Mar; 12(1):5377. PubMed ID: 35354899
[TBL] [Abstract][Full Text] [Related]
13. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.
Wang T; Zhou Q; Zeng H; Zhang H; Liu Z; Shao J; Wang Z; Xiong Y; Wang J; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Chang Y; Wang X; Xu J
Cancer Immunol Immunother; 2020 Sep; 69(9):1855-1867. PubMed ID: 32367308
[TBL] [Abstract][Full Text] [Related]
14. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
15. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
Front Immunol; 2018; 9():3119. PubMed ID: 30687323
[TBL] [Abstract][Full Text] [Related]
16. Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1
Wang M; Qin Z; Wan J; Yan Y; Duan X; Yao X; Jiang Z; Li W; Qin Z
Cancer Immunol Immunother; 2022 Nov; 71(11):2717-2730. PubMed ID: 35428909
[TBL] [Abstract][Full Text] [Related]
17. A Novel Prognostic Biomarker CCR8 for Gastric Cancer and Anti-CCR8 Blockade Attenuate the Immunosuppressive Capacity of Tregs
Zhang Z; Wang G; Shao X; Wu H; Su X; Zhu L; Ji Z
Cancer Biother Radiopharm; 2023 Aug; 38(6):415-424. PubMed ID: 37102694
[No Abstract] [Full Text] [Related]
18. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.
Hindley JP; Ferreira C; Jones E; Lauder SN; Ladell K; Wynn KK; Betts GJ; Singh Y; Price DA; Godkin AJ; Dyson J; Gallimore A
Cancer Res; 2011 Feb; 71(3):736-46. PubMed ID: 21156649
[TBL] [Abstract][Full Text] [Related]
19. CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes.
Soler D; Chapman TR; Poisson LR; Wang L; Cote-Sierra J; Ryan M; McDonald A; Badola S; Fedyk E; Coyle AJ; Hodge MR; Kolbeck R
J Immunol; 2006 Nov; 177(10):6940-51. PubMed ID: 17082609
[TBL] [Abstract][Full Text] [Related]
20. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
